Xcenda in a blog post considers how drug manufacturers can gather evidence to develop their value story before and after launch.
The blog post highlights comparator studies and prospective studies.
“Unlike traditional clinical trials, prospective studies are often unique in their design and objectives, which include collection of longitudinal patient data,” the post states. “In fact, manufacturers can improve the efficiency and outcome of a PS by considering unique, innovative approaches to study design and deployment.”
To read the full blog post, click here.